Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Deferred Revenue (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Current Deferred Revenue for 3 consecutive years, with $23827.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 2.36% to $23827.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23827.0 through Dec 2025, down 2.36% year-over-year, with the annual reading at $23827.0 for FY2025, 2.36% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $23827.0 at bioAffinity Technologies, down from $37915.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $42750.0 in Q2 2023, with the low at $23827.0 in Q4 2025.
  • Average Current Deferred Revenue over 3 years is $29975.0, with a median of $26135.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue crashed 38.87% in 2024, then soared 55.36% in 2025.
  • Over 3 years, Current Deferred Revenue stood at $33058.0 in 2023, then decreased by 26.18% to $24404.0 in 2024, then dropped by 2.36% to $23827.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $23827.0, $37915.0, and $24404.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.